Methods and compositions for determining responsiveness to antibody therapy

Abstract

Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable FcγR polymorphism, e.g., the131 H/H genotype or the158 VN genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.

1 - 43 . (canceled) 
     
     
         44 . A method of detecting the presence of a FcγRIIa 131 H/H genotype in a human subject comprising:
 (a) obtaining a biological sample containing a lymphoma cell from a human subject having non-Hodgkin's lymphoma (NHL); 
 (b) isolating a nucleic acid comprising the FcγRIIa gene from the biological sample; and 
 (c) detecting the presence of a homozygous FcγRIIa 131 H allele in the nucleic acid, thereby detecting the presence of a FcγRIIa 131 H/H genotype in the human subject. 
 
     
     
         45 . The method according to  claim 44 , wherein said detecting comprises amplifying a portion of the FcγRIIa gene sequence comprising nucleic acids encoding amino acid residue 131 from the nucleic acid sample. 
     
     
         46 . The method according to  claim 45 , comprising sequencing the amplified nucleic acid. 
     
     
         47 . The method according to  claim 44 , wherein detecting comprises a nucleic acid probe that specifically hybridizes to a FcγRIIa nucleic acid encoding histidine (H) at amino acid residue 131. 
     
     
         48 . The method according to  claim 44 , wherein the method further comprises detecting the FcγRIIIa 158 genotype. 
     
     
         49 . The method according to  claim 48 , wherein the FcγRIIIa 158 genotype is a 158 V/V, 158 V/F, or 158 F/F genotype. 
     
     
         50 . The method according to  claim 44 , wherein said NHL is follicular lymphoma. 
     
     
         51 . The method according to  claim 44 , wherein the human subject has been administered an IgG anti-CD20 antibody. 
     
     
         52 . The method according to  claim 51 , wherein said IgG anti-CD20 antibody is a monoclonal antibody. 
     
     
         53 . The method according to  claim 52 , wherein said monoclonal antibody is rituximab.